RxDoctor Payments Data

Cathyleen Filippi, APRN

Nurse Practitioner · Vero Beach, FLNPI 1598313256

Payments from drug & device makers

$12,739in general payments, 2019–2025

Across 374 payments — averaging $34.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$4K
  • Valencia Technologies Corporation$1K
  • Astellas Pharma US Inc$837
  • Johnson & Johnson$489
  • Bioprotect Medical, Inc.$453
  • Seagen Inc.$423
  • plus $5K from 54 others

What the payments were for

  • Speaking & faculty fees$310%
  • Travel & lodging$2,55220%
  • Food & beverage$9,49575%
  • Education$6625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Axonics, Inc.56$3,921
Valencia Technologies Corporation2$1,030
Astellas Pharma US Inc15$837
Johnson & Johnson22$489
Bioprotect Medical, Inc.4$453
Seagen Inc.16$423
Novartis22$393
Coloplast8$388
Boston Scientific9$315
Incyte Corporation13$310
Merck13$289
Procept Biorobotics Corporation2$262
Bayer13$253
Amgen14$239
Pfizer12$206
Jazz Pharmaceuticals Inc.11$197
Daiichi Sankyo Inc.9$174
E.r. Squibb & Sons, L.L.C.9$164
Sanofi9$145
AstraZeneca(2 entities)7$140
Myriad Genetic Laboratories, Inc.6$117
Sumitomo Pharma America, Inc.4$111
Teleflex LLC3$99
Sun Pharmaceutical Industries Inc.4$89
Regeneron Healthcare Solutions, Inc.5$75
Morphosys, US Inc.5$73
Urogen Pharma, Inc.3$71
Puma Biotechnology, Inc.5$70
Taiho Oncology, Inc.4$66
Pharmacosmos Therapeutics Inc.3$62
GSK4$62
Myovant Sciences Inc.3$60
Stemline Therapeutics Inc.3$59
Vertex2$57
AVEO Pharmaceuticals, Inc.2$55
Dova Pharmaceuticals4$54
Lilly USA, LLC2$52
Eisai Inc.3$52
Bristol Myers Squibb3$48
Accord Healthcare, Inc.3$47
Takeda Pharmaceuticals U.S.A., Inc.2$46
Tersera Therapeutics LLC2$43
Ipsen Biopharmaceuticals, Inc2$41
Pharmacyclics LLC, An Abbvie Company2$34
Laborie Medical Technologies Corp.2$31
Medtronic1$28
EMD Serono, Inc.1$28
Karyopharm Therapeutics Inc.2$27
Adaptive Biotechnologies Corporation1$26
180 Medical, Inc.1$25
Progenics Pharmaceuticals, Inc.1$24
Ferring Pharmaceuticals Inc.1$23
AMAG Pharmaceuticals, Inc.1$23
AbbVie1$22
Tolmar, Inc.1$21
Servier Pharmaceuticals LLC1$21
EUSA Pharma (US) LLC1$21
Alnylam Pharmaceuticals Inc.1$21
Kyowa Kirin, Inc.1$20
Acrotech Biopharma Inc.1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,739 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$17,423
Medicare patients
120
Services billed
252

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$154,244
OrgovyxRelugolix29$75,715
GemtesaVibegron37$33,241
MyrbetriqMirabegron17$19,474
Tamsulosin Hcl339$6,367
Methenamine Hippurate36$5,439
Testosterone15$4,092
Estradiol51$2,811
Testosterone Cypionate22$1,220
Finasteride83$1,181
Solifenacin Succinate15$558
Trospium Chloride12$545
Alfuzosin Hcl ErAlfuzosin Hcl12$280
Cephalexin107$255
Oxybutynin Chloride ErOxybutynin Chloride67$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$837$173,71829 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$111$108,95666 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →